“Covid arm”: Abnormal side effect after Moderna COVID ‐19 vaccineLetter Published on 2021-11-162022-10-31 Journal: Dermatologic therapy [Category] COVID-19, MERS, SARS, [키워드] COVID Moderna Side effect Vaccine [DOI] 10.1111/dth.15197 PMC 바로가기 [Article Type] Letter
Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance DatabaseArticle Published on 2021-11-152022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] Adverse Adverse drug reaction adverse event adverse events AstraZenaca clinical Clinical outcome conducted COVID-19 COVID-19 vaccine COVID-19 vaccines database described Descriptive analysis determine fatality Frequency Moderna Occurrence outcome Oxford-AstraZeneca pandemic Pfizer reported retrospective Serious Adverse Events significantly submitted thrombotic Vaccine Vaccines were recorded while [DOI] 10.3390/vaccines9111326 PMC 바로가기 [Article Type] Article
Community Pharmacist-Administered COVID-19 Vaccinations: A Pilot Customer Survey on Satisfaction and Motivation to Get VaccinatedArticle Published on 2021-11-142022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] administer Administered age approved Community Community pharmacy Complete concerning coronavirus disease COVID-19 COVID-19 vaccination COVID-19 vaccine Customer dose Health authority information injection men Moderna MOST motivation mRNA mRNA vaccine pandemic pharmacies Pharmacy pre-vaccination questionnaire Questionnaires receiving reported SARS-CoV-2 Satisfaction satisfaction questionnaire survey Switzerland vaccination women [DOI] 10.3390/vaccines9111320 PMC 바로가기 [Article Type] Article
Case Report: Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis With Acute Renal Failure and Pulmonary Hemorrhage May Occur After COVID-19 VaccinationMedicine Published on 2021-11-112022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] acute renal failure administration anti-CD20 therapy anti-neutrophil cytoplasmic antibody (ANCA) antibody coronavirus disease COVID-19 COVID-19 mRNA Vaccination COVID-19 vaccination cytoplasmic failure first dose gross hematuria hemoptysis increase in instance management Moderna nasopharyngeal plasma polymerase chain pulmonary pulmonary hemorrhage pulmonary renal syndrome renal renal biopsy renal function resolved resulting RNA virus serum serum creatinine severe adverse effect susceptible patient syndrome Systemic steroid Urinalysis vaccination Vasculitis [DOI] 10.3389/fmed.2021.765447 PMC 바로가기 [Article Type] Medicine
Minimal change disease following the Moderna COVID-19 vaccine: first case reportCase Report Published on 2021-11-112022-10-28 Journal: BMC Nephrology [Category] COVID-19, MERS, SARS, [키워드] bases blood pressure Case report COVID-19 COVID-19 mRNA vaccine COVID-19 vaccine determine disease Dyspnea edema first dose glomerular hospital hyperlipidemia IgA nephropathy immunization incidence Injury knowledge lung minimal change disease Moderna nephrotic syndrome oral steroid pathophysiology Pfizer-BioNTech Physical examination post vaccination Post-vaccine receiving renal biopsy reported resolved scrotal edema serum albumin treated Treatment vaccination Vaccine Vaccines [DOI] 10.1186/s12882-021-02583-9 PMC 바로가기 [Article Type] Case Report
Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 VaccinesResearch Article Published on 2021-11-102022-10-30 Journal: Microbiology Spectrum [Category] COVID-19, [키워드] age and gender antibodies antibody antibody kinetics Antibody Response average binding domain BNT162b2 BNT162b2 vaccine changes in clinically clinician Cohort COVID-19 COVID-19 pandemic defined difference dosage dose regimen elicited first dose Follow-up human cell IgG IgG antibody IgG response immune system immunization immunosuppressive drugs linear Moderna mRNA mRNA platform mRNA vaccine mRNA-1273 mRNA-1273 vaccine overcome participant peaked Pfizer/BioNTech powerful tool Prospective regimens regression modeling remained response S-protein SARS-CoV-2 SARS-CoV-2 vaccine second dose seroconverted serological Serologically seronegative participants significantly higher Spike protein the SARS-CoV-2 the vaccine titer translated vaccination Vaccine Vaccines virus spike protein was used were measured [DOI] 10.1128/Spectrum.01162-21 PMC 바로가기 [Article Type] Research Article
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trialResearch article Published on 2021-11-092022-10-05 Journal: The Lancet. Oncology [Category] SARS, 임상, [키워드] 95% CI adverse event Against analysed Analysis antibody Antibody Response baseline benefit binding antibody unit Cancer cancer treatment Chemotherapy Cohort Complication Concentration COVID COVID-19 COVID-19 vaccination COVID-19 vaccine deaths defined develop development diarrhoea enrolled event febrile neutropenia Fever finding funding grade 3 histology IgG Immunotherapy increased risk individual individuals without cancer intramuscularly IQR margin median Moderna Most patient mRNA-1273 mRNA-1273 COVID-19 vaccine multicentre Netherland Netherlands non-inferiority design non-inferiority trial occurred Older participant Patient patient cohort patients per protocol positive Prevent primary endpoint receiving recorded Registered Safe SARS-COV-2 infection second vaccination Serious Adverse Event Seroconversion serum antibody response solid tumour Spain the primary endpoint the SARS-CoV-2 treated Trial Tumours vaccination Vaccine was done was used [DOI] 10.1016/S1470-2045(21)00574-X [Article Type] Research article
Comparative safety of mRNA COVID‐19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international databaseResearch Article Published on 2021-11-082022-10-04 Journal: Journal of medical virology [Category] Fulltext, MERS, 진단, [키워드] 95% CI 95% confidence interval adjusted adverse event AEs Analysis cardiovascular complications Comparative COVID‐19 COVID‐19 database demonstrated detect Evidence fatigue hypertensive immunization individual Influenza influenza vaccine influenza vaccines injection International Loss of consciousness lower risk Messenger RNA Moderna mRNA mRNA vaccination mRNA vaccine mRNA vaccines myalgia Neurological complication Odds ratio Pfizer‐BioNTech post‐implementation surveillance prevalent previous study reaction reactogenicity event reported risk Safety safety profile significantly higher suggested supraventricular Syncope syndrome Tachycardia vaccinated individual Vaccine Vaccines VigiBase visual impairment Volume WHO [DOI] 10.1002/jmv.27424 PMC 바로가기 [Article Type] Research Article
The Critical Contribution of Pseudouridine to mRNA COVID-19 VaccinesCell and Developmental Biology Published on 2021-11-042022-10-31 Journal: Frontiers in Cell and Developmental Biology [Category] COVID-19, [키워드] clinical trial COVID-19 COVID-19 case COVID-19 mRNA vaccines COVID-19 pandemic COVID-19 vaccine Critical death effective Efficacy feature FIVE highlight Lipid nanoparticles LNP Moderna mRNA mRNA vaccine mRNA vaccines N1-methyl-pseudouridine pandemic Pfizer-BioNTech presenting Protein pseudouridine RNA modification SARS-CoV-2 sequence spike Spike protein suggested Therapeutics Vaccine Vaccines [DOI] 10.3389/fcell.2021.789427 PMC 바로가기 [Article Type] Cell and Developmental Biology
LB9. Longitudinal antibody dynamics in children infected with SARS-CoV-2 through 6 months post-infectionLate Breaker Abstracts Published on 2021-11-042022-10-29 Journal: Open Forum Infectious Diseases [Category] COVID-19, [키워드] Abbott acute respiratory syndrome antibody Antibody titer Architect AstraZeneca binding Blood blood sample CDC changes in children collected Community consultant convalescent sera coronavirus COVID-19 vaccine decrease detectable Diagnosis elicit enrolled evaluate examined figure Flagship GlaxoSmithKline had no Hospitalized Immunocompromised Immunosuppression include infected with SARS-CoV-2 Infection Jesse laboratory-confirmed SARS-CoV-2 infection longitudinal Meissa Moderna neutralization potency neutralization titer Neutralizing Neutralizing activity neutralizing titers nucleocapsid Outpatient participant Pfizer pharmaceutical Post-infection Protein provided recruited reduction Result Sanofi Pasteur SARS-CoV-2 SARS-CoV-2 immunity Seattle Children’s Hospital supported symptomatic and asymptomatic symptomatic disease undetectable Viral protein Volunteer were assessed with COVID-19 [DOI] 10.1093/ofid/ofab466.1640 PMC 바로가기 [Article Type] Late Breaker Abstracts